ArticleEMBO reports2026
3D chromatin organisation contributes to the regulatory logic in differentiating lymphatic endothelium.
Article in EMBO reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
Gene activation and repression is an integral part of embryonic development and tissue formation. Changes in chromatin organisation dictate accessibility to gene regulatory elements, controlling gene expression. Although several molecular regulators of lymphatic endothelial cell (LEC) development have been identified, the role of chromatin organisation in the acquisition of LEC identity remains unclear. In this study, we combine HiC and ATAC-sequencing to map 3D chromatin architecture and accessibility in LECs and blood endothelial cells (BECs). We identify cell type-specific topologically associating domains (TADs), and discovered TAD boundaries changes and differentially segregating enhancers in lymphatic-associated loci, such as prox1a and tbx1. Our multi-omic approach also defines the regulatory logic of nine LEC-enriched genes. In vivo validation of ATAC- and HiC-based enhancers confirms their activity in LECs. Leveraging these datasets, we reconstructed mafba tissue-specific regulatory networks identifying a genetic interaction with tfe3a in vivo limiting ectopic vessel formation. Overall, our work provides a powerful resource of multi-omic datasets that can be used to systematically determine the regulatory networks governing LEC identity and genes linked to lymphatic disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.